Global Cell Therapy Market & Clinical Pipeline Outlook

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
89
Global Cell Therapy Market & Clinical Pipeline Outlook 2022: 476 Drugs by Country, Indication & Phase

Dublin, Feb. 03, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Cell Therapy Market & Clinical Pipeline Outlook 2022" report to their offering. The Global Cell Therapy Market & Clinical Pipeline Outlook 2022 report gives comprehensive insight on the ongoing clinical and nonclinical trends in the global cell therapy market.

Report analyzes the need and the application of cell therapy in multiple therapeutic areas along with the mechanism and delivery methods for cell therapy based treatment. The parameters impacting the growth of the market and the corresponding challenges limiting the commercialization of cell therapies are explained in the report. The idea of cell therapy was in pharmaceutical industry for several decades but significant development was not made due to technological challenges. In recent years, cell therapy has gained widespread acceptance among physicians and patients due to its ability to treat various diseases. Several decades of research and development has allowed the investigators to come forth with solutions which can't be provided by conventional therapeutics. Theoretically, it could be used to cure plethora of diseases but underdeveloped technology has limited its usage to limited indications. Several indications have been found to be curable with the help of cell therapies and indications are expected to be increased in near future. Cerebral disorders like Parkinson's disease and Alzheimer's disease are under investigation for treatment with the help of cell therapies. They are also being investigated for cardiovascular disease in which their aim is to restore normal heart functions. Investigators are also trying to find their safety and efficacy in treating various malignancies. On-going research is also aimed at curing metabolic disorder like diabetes mellitus type 1 in which patients tends to lack insulin production. Investigators are trying to restore the function of liver and kidney by supplementing them with modified cell of respective origins. Several clinical trials have been instigated across the globe in which their efficacy against different disease is being studies. Global Cell Therapy Market & Clinical Pipeline Outlook 2022 Highlights: - Introduction & Classification of Cell Therapies - Mechanism of Cell Therapy - Global Cell Therapy Market Analysis - Role of Stem Cells in Cell Therapy - Global Cell Therapy Clinical Pipeline by Country, Indication & Phase - Global Cell Therapy Clinical Pipeline: 476 - Marketed Cell Therapies: 20 Key Topics Covered: 1. Introduction to Cell Therapy 2. Necessity for Cell Therapy Treatment 2.1 Emergence of Stem Cell Research 2.2 Benefits of Using the Stem Cell for Research & Treatment 3. Application of Stem Cells in Cell Therapy 3.1 Stem Cells Ability to Differentiate 3.1.1 Totipotent Stem Cells 3.1.2 Pluripotent Stem Cells 3.1.3 Multipotent Stem Cells 3.1.4 Unipotent Stem Cells 3.2 Origin of Stem Cells 3.2.1 Embryonic Stem Cells 3.2.2 Adult Stem Cells 3.2.3 Induced Pluripotent Stem Cells (iPSCs) 4. Applications of Cell Therapy by Therapeutic Area 4.1 Cell Therapy for Cardiovascular Diseases 4.2 Cell Therapy for Neurological Disorders 4.3 Cell Therapy for Inflammatory Diseases 4.4 Cell Therapy for Diabetes 4.5 Cell Therapy for Cancer 4.6 Cancer Stem Cells Therapy 5. Mechanism of Cell Therapy 5.1 Two Major Mechanism Principles of Stem Cell Based Therapy 5.2 Mechanism of Action in Alzheimer's Diseases 6. Delivery Method of Cell Based Therapy 6.1 Outline to Delivery Methods 6.2 Direct Delivery Methods 6.3 Indirect Delivery of the Cells by Using the Carrier 7. Mechanism of Cell Therapy Treatment 7.1 Allogeneic Stem Cell Therapy 7.2 Autologous Stem Cell Therapy 8. Global Cell Therapy Market Overview 8.1 Current Market Scenario 8.2 Current Trends of Cell Therapy in Global Market 8.3 Global Cell Therapies Clinical Pipeline Overview 9. Global Cell Therapy Market by Region 9.1 North America 9.2 Europe 9.3 Asia 9.4 Rest of the World 10. Global Cell Therapy Market Dynamics 10.1 Favorable Market Parameters 10.2 Factors Limiting Market Growth 11. Global Cell Therapy Market Future Prospect 12. Global Cell Therapies Clinical Pipeline by Company, Indication & Phase 12.1 Unknown 12.2 Research 12.3 Preclinical 12.4 Clinical 12.5 Phase-0 12.6 Phase-I 12.7 Phase-I/II 12.8 Phase-II 12.9 Phase-II/III 12.10 Phase-III 12.11 Preregistration 12.12 Registered 13. Marketed Cell Therapies Clinical Insight by Company & Indication 13.1 T-Lymphocyte Cell Therapy (Immuncell-LC) 13.2 Muscle-Derived Autologous Stem Cell Therapy (MyoCell & MyoCell SDF-1) 13.3 Azficel-T (Laviv) 13.4 Sipuleucel-T (Provenge) 13.5 Placental Derived Mesenchymal Stem Cell Therapy - Osiris Therapeutics 13.6 Remestemcel-L (Prochymal & TEMCELL HS Inj.) 13.7 Autologous Mesenchymal Stem Cell Therapy - Pharmicell 13.8 Autologous Cultured Chondrocytes (MACI) 13.9 Mesenchymal Stem Cell Therapy for Cartilage Repair (Cartistem) 13.10 Leukocyte Cell Therapy (CureXcell) 13.11 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell) 13.12 Allogeneic Cultured Keratinocytes and Fibroblasts (Gintuit) 13.13 Autologous Cultured Chondrocyte Implant (Carticel) 13.14 Autologous Cultured Chondrocytes (CHONDRON) 13.15 Autologous Chondrocytes (BioCart & BioCartII) 13.16 Amniotic Cell Therapy (NuCel) 13.17 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical 13.18 Autologous Cultured Chondrocytes (Chondrotransplant DISC) 13.19 Autologous Cultured Myoblasts and Fibroblasts (Urocell) 13.20 Human Skin Replacement (CellSpray & CellSpray XP) 14. Competitive Landscape 14.1 AlloCure 14.2 Arteriocyte Medical Systems 14.3 Athersys Inc. 14.4 Baxter Healthcare Corporation 14.5 Bone Therapeutics 14.6 Celgene Corporation 14.7 Cell Medica 14.8 Cellerant Therapeutics 14.9 FibrocellScinence 14.10 Forticell Bioscience 14.11 Genzyme Corporation 14.12 Green Cross Cell 14.13 Histogenics Corporation 14.14 InnovacellBiotechnologie AG 14.15 Intrexon Corporation 14.16 Intercytex 14.17 ISTO Technologies 14.18 Macrocure 14.19 Mesoblast 14.20 Molmed 14.21 Nuo Therapeutics Inc 14.22 OmniCyte 14.23 Opexa Therapeutics 14.24 Organogenesis 14.25 Pharmicell 14.26 TCA Cellular Therapy 14.27 Stem Cell Inc. 14.28 Teva Pharmaceuticals 14.29 Tigenix 14.30 Vericel Corporation For more information about this report visit http://www.researchandmarkets.com/research/m7...lobal_cell

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Genomics

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 392

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 139

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 255

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 253

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 204

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 203

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 200

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 281

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 166

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading

Top 5 Most Recently Viewed Articles

AngioDynamics' NanoKnife® System Receives FDA Clearance

Updated Category News Views 191

Introduction to AngioDynamics' Innovation AngioDynamics, Inc. (NASDAQ: ANGO), a forward-thinking medical technology firm, has made significant strides in restoring healthy blood flow and enhancing cancer treatment options. Recently, the company announced its accomplishment in receiving FDA 510(k) clearance for its advanced NanoKnife System, specifically designed for...

Continue Reading
Analyst Predicts iPhone Dominance in Apple's Future Revenues

Updated Category News Views 197

Apple's Revenue Outlook and iPhone Influence A recent analysis by Needham paints a promising picture for Apple Inc (NASDAQ: AAPL) as the company prepares for fiscal year 2025. Analyst Laura Martin affirmed a buy rating for Apple, setting an impressive price target of $260. This forecast is based on a well-crafted Discounted Cash Flow (DCF) model, which includes a cash tax...

Continue Reading
Sitetracker's Record Growth and Vision for Future Success

Updated Category News Views 398

Remarkable Achievements in 2024 for Sitetracker Sitetracker has reached significant milestones marking the close of its fiscal year with outstanding growth and exciting plans for the upcoming year. As a leader in the field of asset lifecycle management, they have positioned themselves strongly in markets worldwide, focusing on providing tools for various critical...

Continue Reading
Olympus Showcases Innovative ENT Solutions at Major Meetings

Updated Category News Views 176

Olympus Highlights Cutting-Edge ENT Solutions Olympus Corporation of the Americas, a leading medical technology company committed to enhancing health and safety, will unveil its extensive ENT portfolio at upcoming annual physician meetings. Attendees will have the opportunity to see how Olympus integrates hybrid endoscopy with advanced imaging and content management...

Continue Reading
Exciting Launch of Tech Mahindra Chess League Season 3

Updated Category News Views 101

Tech Mahindra Global Chess League Season 3 Launches with Excitement The Global Chess League (GCL) has officially begun its Season 3, and excitement fills the air as six teams are set to compete in 34 matches for the coveted championship trophy. The league kicked off at Mumbai's Royal Opera House, a perfect venue for this grand event. Spectacular Opening Ceremony in Mumbai...

Continue Reading